Blog

Misty Dawn Shields: Great discussion on NSCLC at Texas Lung Cancer Conference 2025

Misty Dawn Shields/X

Apr 14, 2025, 09:32

Misty Dawn Shields: Great discussion on NSCLC at Texas Lung Cancer Conference 2025

Misty Dawn Shields, Assistant Professor at Indiana University School of Medicine, shared a post on X:

“A rapidly evolving landscape for KRAS G12C and non-G12C, HER2, MET ex14skipping, and BRAF altered NSCLC. Great discussion among the experts at Texas Lung 25 capturing the nuances of this important topic.”

cancer Misty Dawn Shields NSCLC OncoDaily Oncology Texas Lung 25

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023

Facebook

Youtube

Blog

Aug 1, 2025, 18:32

Sharon Kapambwe: Representing WHO in Uzbekistan

Blog

Aug 1, 2025, 18:14

Turn Knowledge Into Expertise and Refined Practical Skills - European School of Oncology

Blog

Aug 1, 2025, 18:02

"Moving Mountains With Passion": A Legacy of Purpose in European Oncology - CancerWorld

Positive

Aug 1, 2025, 17:56

Miriam Mutebi: Honored to Be Recognized at the 2nd NCI Kenya Summit

Insight

Aug 1, 2025, 17:48

Sketchnoting: Making Complex Scientific Concepts More Accessible - St. Jude Children's Research Hospital

Blog

Aug 1, 2025, 17:42

The Best Part of Palliative Care TOTs Isn’t Just the Skills - ACREOL Global

Oncolibrary

Aug 1, 2025, 17:40

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Blog

Aug 1, 2025, 17:26

International Consensus Guideline on Delineation of CTV for Nasopharyngeal Carcinoma

Blog

Aug 1, 2025, 17:11

Shilpa Gupta: Honored to Chair the Bladder Cancer Advocacy Network with My Co-Chair Max Kates

Blog

Aug 1, 2025, 17:11

Maintaining High-Quality Data to be Able to Generate Robust Local Evidence - CANCaRe Africa

Science

Aug 1, 2025, 16:40

Could Radiotherapy Help "Cold" Lung Cancer Tumours Respond to Immunotherapy? - Lung Cancer Europe

Blog

Aug 1, 2025, 16:40

Antonio Cigliola: Honored to Receive the 2025 BCAN John Quale Travel Fellowship